Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GE Healthcare

- PMLiVE

Sanofi and AI specialist Aqemia enter $140m drug discovery partnership

The deal is aimed at discovering small molecule drugs across several therapeutic areas

- PMLiVE

AstraZeneca and generative AI company Absci enter $247m oncology partnership

The collaboration is aimed at developing an AI-designed antibody drug for an oncology target

- PMLiVE

Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn

The company will gain access to a portfolio of incretin-based therapies for diabetes and obesity

- PMLiVE

Cancer Research UK and Guardant collaborate to advance cancer detection and treatment

The partnership aims to accelerate the development of cancer drugs and diagnostics

- PMLiVE

The Power of the Partnership: How Patient-Centricity Improves Care

How can the patient’s voice improve care?This was the question Medscape Oncology Clinical Strategist Victoria Harvey-Jones, PhD and Lesley Fallowfield DBE, BSC, DPHIL, FMEDSCI, Professor of Pyscho-Oncology, Sussex Health Outcomes...

Medscape Education Global

- PMLiVE

AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition

The agreement grants the company access to FDA-approved ovarian cancer drug Elahere

- PMLiVE

FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies

The regulator will monitor approved BCMA- or CD19-directed autologous CAR-T cell immunotherapies

- PMLiVE

Planting the Seeds for Future Women Leaders in Medicine

What are the qualities needed to be a leader in the medical field of oncology?Of course, you must be a good clinician. But you also have to be wise and...

Medscape Education Global

- PMLiVE

GSK shares positive phase 3 results for Blenrep combination in multiple myeloma

Approximately 176,000 new cases of multiple myeloma are diagnosed globally each year

- PMLiVE

FDA approves SpringWork’s Ogsiveo as first therapy for desmoid tumours

Approximately 1,650 people in the US are diagnosed with the rare non-cancerous tumours each year

- PMLiVE

Cancer Research UK calls on government to create ten-year cancer plan

The charity estimates that around 20,000 annual cancer deaths in the UK could be prevented by 2040

- PMLiVE

AstraZeneca gains rights to Usynova’s KRAS inhibitor in deal worth almost $420m

There are currently no approved drugs specifically targeting the KRAS G12D mutation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links